Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072356 · ClinicalTrials.gov registry record · Early Phase 1
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
A Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 290
- Enrollment target
NCT02072356 is a Early Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 290 participants.
The verdict
NCT02072356, a Early Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 290 participants
- Enrollment target
Study Summary
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be an effective treatment for liver cancer.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION yttrium Y 90 glass microspheres
- DRUG TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2010-10-11 |
| Est. Completion | 2021-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072356
The ClinicalTrials.gov registry entry for NCT02072356 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02072356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072356 about?
NCT02072356 is a clinical study titled "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery". This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kil...
What is the current status of trial NCT02072356?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 290 participants. The study started on 2010-10-11. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02072356?
The interventions under investigation include: laboratory biomarker analysis (OTHER), yttrium Y 90 glass microspheres (RADIATION), TheraSphere (DRUG).
Who is sponsoring clinical trial NCT02072356?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.